Citations 2
NCCN Guidelines Insights: Management of Immunotherapy-Related Toxicities, Version 1.2020
Thompson, John A. , Schneider, Bryan J. , Brahmer, Julie R. , Andrews, Stephanie, Armand, Philippe , Davies, Marianne, Dunnington, David, Frigault, Matthew J. , Kaffenberger, Benjamin H. , Lunning, Matthew A. , McGettigan, Suzanne , McPherson, Jordan P. , Mohindra, Nisha , Naidoo, Jarushka , Olszanski, Anthony J. , Oluwole, Olalekan O. , Patel, Sandip Pravin , Reddy, Sunil , Ryder, Mabel , Santomasso, Bianca , Shofer, Scott , Sosman, Jeffrey A. , Weight, Ryan , Johnson-Chilla, Alyse, Zuccarino-Catania, Griselda, Engh, Anita M. , Oluwole, Olalekan O , Naidoo, Jarushka , Olszanski, Anthony J , Kaffenberger, B , Ryder, Mabel , Bhatia, Shailender , Budde, Lihua E. , Costa, Luciano J. , Ernstoff, Marc S. , Pennell, Nathan A , Wang, Yinghong
Journal of the National Comprehensive Cancer Network | March 5, 2020 | Volume: 18 | Issue: 3 | Pages: 230-241
The NCCN Guidelines for Management of Immunotherapy-Related Toxicities provide interdisciplinary guidance on the management of immune-related adverse events (irAEs) resulting from cancer immunotherapy. These NCCN Guidelines Insights describe symptoms that may be caused by an irAE and should trigger further investigation, and summarize the NCCN Management of Immunotherapy-Related Toxicities Panel discussions for the 2020 update to the guidelines regarding immune checkpoint inhibitor–related diarrhea/colitis and cardiovascular irAEs.
NCCN Guidelines Insights: Kidney Cancer, Version 2.2020
Michaelson, M. Dror , Nandagopal, Lakshminarayanan , George, Saby , Alva, Ajjai , Harrison, Michael R. , Sosman, Jeffrey A. , Bhayani, Sam B., Choueiri, Toni K. , Costello, Brian A. , Derweesh, Ithaar , Kyriakopoulos, Christos E. , LaGrange, Chad A. , Lau, Clayton, Lewis, Bryan , McCreery, Brittany, McDonald, Andrew , Mortazavi, Amir , Ponsky, Lee , Redman, Bruce G., Somer, Bradley G. , Wile, Geoffrey, Dwyer, Mary A., CGC, Hammond, Lydia J., Zuccarino-Catania, Griselda, Choueiri, Toni K , Motzer, Robert J. , Jonasch, Eric W. , Gore, John L. , Haas, Naomi B , Plimack, Elizabeth R. , Agarwal, Neeraj , Gallagher, Thomas H. , Hancock, Steven Lee , Lam, Elaine T. , Manley, Brandon J. , Pierorazio, Phillip , CGC
Journal of the National Comprehensive Cancer Network | November 7, 2019 | Volume: 17 | Issue: 11 | Pages: 1278-1285
The NCCN Guidelines for Kidney Cancer provide multidisciplinary recommendations for the clinical management of patients with clear cell and non–clear cell renal cell carcinoma, and are intended to assist with clinical decision-making. These NCCN Guidelines Insights summarize the NCCN Kidney Cancer Panel discussions for the 2020 update to the guidelines regarding initial management and first-line systemic therapy options for patients with advanced clear cell renal cell carcinoma.